We recently released our:

Clinical Recommendations For The Use Of Benralizumab In Severe Asthma

This document was developed by the Centre of Excellence in Severe Asthma. It provides an overview of benralizumab treatment, eligibility criteria, enrolment, precautions/adverse effects and procedures for administration. This document has been developed as a guide only. Any local recommendations and requirements must be considered when implementing these recommendations into practice.

Download the document by clicking on the image below:

You can learn more about Monoclonal Antibodies as add-on therapies for severe asthma at the Severe Asthma Toolkit.